Back to News
Market Impact: 0.25
FDA Confirms SeaStar Medical Meets QUELIMMUNE Post-Approval Study Requirements
Source: Nasdaq
Healthcare & BiotechRegulation & Legislation
SeaStar Medical said the FDA determined that its QUELIMMUNE Pediatric SAVE Surveillance Registry fulfilled the post-approval study requirements under the device’s original Humanitarian Device Exemption. The report provides no additional study results or financial figures.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
ICU0.70
More News
- 5 things to watch on Election Day as Democrats push for control of Congress
- Investors poised for possible Democratic gains in Congress as US awaits election results
- Texas race results could kick AI trade while it's already down
- Analysts react to US midterm election results
- Fannie Mae, Freddie Mac rally as Ackman presses for conservatorship exit
- Meta says automation wrongly took down No Kings and a Senate candidate’s page. It’s automating more anyway